Netherlands· NL-104536ebea7e

Selexipag Abdi 800 microgram filmomhulde tabletten

A selexipag product containing selexipag, registered in Netherlands by Abdi Farma GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC B01AC27

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about selexipagAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Selexipag is registered in 13 of 19 countries.

Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search selexipag products by name

Selexipag · ATC B01AC27

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selexipag costs, country by country.

Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Selexipag · price per daily dose (1.8 mg)

USD · FX 28 Sept 2026

IT Italy$1232.99
CH Switzerland$809.99

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: SELEXIPAG
Manufacturer: Abdi Farma GmbH
Country: Netherlands (NL)
ATC code: B01AC27
ATC class: Selexipag
Defined daily dose: 1.8 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
133730

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

237 interactions on record for selexipag.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check selexipag against other medicines How interaction checks work

Selexipag · interactions on record

237 records

1 severe
232 moderate
4 minor

Most severe, free to view

GemfibrozilC10AB04severe
PapaverineA03AD01moderate
MannitolA06AD16moderate
GlycerolA06AX01moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selexipag in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selexipag products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

Austria · Selexipag Ratiopharm
Cyprus · Selexipag Accord
Denmark · Selexipag Accord, Selexipag Stada
Estonia · Selexipag Stada
Spain · Selexipag Accord, Selexipag Stada
Greece · Xipeno
Croatia · Seleksipag Accord
Ireland · Selexipag Accord, Selexipag Clonmel
Iceland · Selexipag Stada, Uptravi
Italy · Selexipag Accord, Selexipag Eg
Liechtenstein · Uptravi
Lithuania · Selexipag Stada
Latvia · Selexipag Stada
Malta · Selexipag Clonmel
Norway · Selexipag Accord, Selexipag Stada
Poland · Selexipag, Selexipag Accord
Portugal · Selexipag Accord, Selexipag Teva
Sweden · Selexipag, Selexipag Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/9fa63448-15da-4f81-a1b1-4f636a962cd5
GET /v1/drugs/9fa63448-15da-4f81-a1b1-4f636a962cd5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h133730_smpc.pdf",
  "strength": null,
  "atc_label": "Selexipag",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133730",
  "excipients": [
    "CARNAUBAWAS (E 903)",
    "HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "LACTOSE 1-WATER",
    "MAÏSZETMEEL",
    "NATRIUMSTEARYLFUMARAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "SELEXIPAG"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133730.pdf",
  "authorised_at": "2026/05/04",
  "procedure_number": "NL/H/6216/004",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "133730",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about selexipag.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console